Study on pharmacokinetic features of Repaglinide and the influence of genetic polymorphisms on its pharmacokinetics and drug interactions

Abstract

Abstract: Repaglinide is a novel non-sulfonylurea oral hypoglycemic agent by stimulating insulin secretion, with a structure of amino acid profile.Its action occurs rapidly and sustains shortly.By simulating the physiology secretion of insulin, it majors in controlling hyperglycemia and reduces the incident of hypoglycemia.In this paper,we will give a review about the pharmacokinetic features, genomics research progress, drug interaction of repaglinide,in order to lay down a solid theory foundation for the guidance in clinical usage of repaglinide, ensure the safety and effectiveness of clinical usage, achieving individualized therapy in its true sense.

Key words: Repaglinide, Pharmacokinetic feature, Genetic polymorphism, Individualized therapy

CLC Number:

R969

SUN Xu,YUAN Zhao,WEN Jin-hua,XIONG Yu-qing. Study on pharmacokinetic features of Repaglinide and the influence of genetic polymorphisms on its pharmacokinetics and drug interactions[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2011, 16(4): 468-473.

References

[1] Owens DR. Repaglinide - prandial glucose regulator: a new class of oral antidiabetic drugs[J]. Diabet Med, 1999,15(4): S28-S36.
[2] 杨华章,陈亮,崔炎棠. 降糖新药瑞格列奈的研究进展[J]. 中国实用内科杂志, 2004, 20(4): 253-254.
[3] 胡晋红, 李珍, 刘晓东, 等. 国产与进口降糖药瑞格列奈片的生物等效性研究[J]. 第二军医大学学报, 2001, 22( 5): 432-434.
[4] Niemi M, Backman JT, Kajosaari LI, et al. Polymorphic organic anion transporting polypeptide 1B1 is a major determinant of repaglinide pharmacokinetics[J]. Clin Pharmacol Ther, 2005, 77(6): 468-478.
[5] Zair ZM, Eloranta JJ, Stieger B, et al. Pharmacogenetics of OATP (SLC21/SLCO), OAT and OCT (SLC22) and PEPT (SLC15) transporters in the intestine, liver and kidney [J]. Pharmacogenomics, 2008, 9(5): 597-624.
[6] Hagenbuch B, Meier PJ. Organic anion transporting polypeptides of the OATP/SLC21 family: phylogenetic classification as OATP/SLCO superfamily, new nomenclature and molecular/functional properties[J]. Pflugers Arch, 2004,447(5): 653-665.
[7] Niemi M. Role of OATP transporters in the disposition of drugs[J]. Pharmacogenomics, 2007, 8(7): 787-802.
[8] Nozawa T, Nakajima M, Tamai I, et al. Genetic polymorphisms of human organic anion transporters OATP2C(SLC21A6) and OATP2B(SLC21A9) : allele frequencies in the Japanese population and functional analysis[J]. J Pharm Acol Exp Ther, 2002,302 (2) :804-813.
[9] Niemi M, Schaeffeler E , Lang T, et al. High plasma pravastatin concentrations are associated with single nucleotide polymorphisms and haplotypes of organic anion transporting polypeptide2C (OATP2C , SLCO1B1) [J].Pharmacogenetics, 2004,14 (7) :429-440.
[10] Kim EY, Cho DY, Shin HJ, et al. Duplex pyrosequencing assay of the 388A > Gand 521T> C SLCO1B1 polymorphisms in three Asian populations [J]. Clin Chim Acta, 2008,388 (1P2) :68-72.
[11] Kameyama Y, Yamashita K, Kobayashi K, et al. Functional characterization of SLCO1B1 (OATP2C) variants, SLCO1B1^*5 , SLCO1B1^*15 and SLCO1B1^*15 +C1007G, by using transient expression systems of HeLa and HEK293 cells[J]. Pharmacogenet Genomics, 2005,15 (7) :513-522.
[12] Kalliokoski A , Backman JT, Neuvonen PJ , et al. Effects of the SLCO1B1^*1B haplotype on the pharmacokinetics and pharmacodynamics of repaglinide and nateglinide [J].Pharmacogenet Genomics , 2008 ,18 (11) :937-942.
[13] Deng JW, Song IS , Shin HJ , et al. The effect of SL2CO1B1^*15 on the disposition of pravastatin and pitavastatin is substrate dependent : the contribution of transporting activity changes by SLCO1B1*15 [J]. Pharmacogenet Genomics, 2008,18 (5) :424-433.
[14] Kalliokoski A, Neuvonen M, Neuvonen PJ, et al. Different effects of SLCO1B1 polymorphism on the pharmacokinetics and pharmacodynamics of repaglinide and nateglinide[J]. J Clin Pharmacol, 2008, 48 (3) : 311-321.
[15] Kalliokoski A , Backman JT, Kurkinen KJ , et al. Effects of Gemfibrozil and Atorvastatin on the Pharmacokinetics of Repaglinide in Relation to SLCO1B1 Polymorphism[J]. Clin Pharmacol Ther, 2008,84 (4) :488-496.
[16] 阳国平, 宋敏, 谭鸿毅, 等.有机阴离子转运多肽1B1(OATP1B1)遗传多态性对瑞格列奈药动学的影响[J].中国临床药理学与治疗学, 2009, 14(9): 990-994.
[17] Bidstrup TB, Bjnsdottir I, Sidelmann UG, et al. CYP2C8 and CYP3A4 are the principal enzymes involved in the human in vitro biotransformation of the insulin secretagogue repaglinide[J].Br J Clin Pharmaco, 2003, l56: 305-314.
[18] Ruzilawati AB, Gan SH. CYP3A4 genetic polymorphism influences repaglinide's pharmacolinetics[J]. Pharmacology,2010,85(6):357-364.
[19] Niemi M, Leathart J B, Neuvonen M, et al. Polymorphism in CYP2C8 is associated with reduced plasma concentrations of repaglinide[J].Clin Pharmacol Ther, 2003, 74(4): 380-387.
[20] Bidstrup TB, Damkier P, Olsen AK, et al. The impact of CYP2C8 polymorphism and grapefruit juice on the pharmacokineties of repaglinide[J]. Br J Clin Pharmacol, 2006, 61(1): 49-57.
[21] Rodríguez-Antona C, Niemi M, Backman JT, et al. Characterization of novel CYP2C8 haplotypes and their contribution to paclitaxel and repaglinide metabolism[J]. Pharmacogenomics J, 2007, 8(4): 268-277.
[22] Hansen AM, Christensen IT, Hansen JB, et al. Differential interactions of nateglinide and repaglinide on the human beta-cell sulphonylurea receptor l[J].Diabetes, 2002, 51(9): 2789-2795.
[23] Hansen AM, Hansen JB, Carr RD, et al. Kir6.2-dependent high-affinity repaglinide binding to beta-cell K(ATP)channels[J].Br J Pharmacol, 2005, 144(4): 551-557.
[24] Tanja BB, Nicolaj S, Per Damkier, et al. Rifampicin seems to act as both an inducer and an inhibitor of the metabolism of repaglinide[J]. Eur J Clin Pharmacol,2004, 60(2): 109-114.
[25] Niemi M, Backman JT, Neuvonen M, et al. Effects of gemfibrozil,itraconazole,and their combination on the pharmacokinetics and pharmacodynamics of repaglinide:potentially hazardous interaction between gemfibrozil and regaplinide[J]. Diabetoligia, 2003, 46(3): 347-351.
[26] Ashfield R, Gribble FM, Ashcroft SJ, et al. Identfication of the high-affinity tolbutamide site on the SURI subunit of the K(ATP)channel[J].Diabetes, 1999, 48(6): 1341-1347.
[27] Kajosaari LI, Niemi M, Neuvonen M, et al. Cyclosporine markedly raises the plasma concentrations of repaglinide[J]. Clin Pharmacol Ther, 2005, 78(4): 388-399.
[28] Kajosaari LI, Jaakkola T, Neuvonen PJ, et al. Pioglitazone, an in vitro inhibitor of CYP2C8 and CYP3A4, does not increase the plasma concentrations of the CYP2C8 and CYP3A4 substrate repaglinide[J]. Eur J Clin Pharmacol, 2006, 62(3): 217-223.
[29] Niemi M, Kajosaari LI, Neuvonen M, et al. The CYP2C8 inhibitor trimethoprim increases the plasmaconcentrations of repaglinide in healthy subjects[J].Br J Clin Pharmacol, 2003, 57(4): 441-447.